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MANAGEMENT OF GENETIC DISEASES:
PRESENT AND FUTURE
TRATAMIENTO DE LAS ENFERMEDADES GENÉTICAS: PRESENTE Y FUTURO
Hugo Hernán Abarca-Barriga1,2,3,a,b, Milana Trubnykova2,a, María del Carmen Castro-Mujica1,a
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ABSTRACT
Today, the number of genetic diseases is around 10000 conditions, affecting to 6%-8% of all populations.
This review shows us how the discovery of genetic variants in our genome, this facilitated to know
with precision about the mechanisms physiopathological, and hence to recognize those target points
susceptible to modifications, through therapeutical strategies different with palliative proposals, increase
life expectancy, or improve qualities of life. These therapies are diverse, using drugs for polygenic diseases,
nutritional therapy, special formulas, enzyme replacement therapies, hematopoietic stem cell transplant,
substrate reduction, oligonucleotides, and gene therapy. These genetic diseases are heterogeneous
clinically with a very low frequency; nevertheless, open to the possibility of research in new strategies for
more genetic disease, that today, furthermore, are orphans.
Key words: Genetic diseases; Genetic Therapy; Hematopoietic Stem Cells; Transplant; Therapy (source:
MeSH NLM).

RESUMEN
El número de enfermedades genéticas se estima que podrían ser más de 10 000 condiciones diferentes,
afectando alrededor del 6-8% de la población. La presente revisión nos muestra la importancia del
descubrimiento de las variantes patogénicas en nuestro genoma que nos permite conocer con mayor
precisión cuales son los mecanismos fisiopatológicos y, por lo tanto, conocer puntos dianas susceptibles
de modificaciones mediante diferentes estrategias terapéuticas para poder palear los síntomas y signos,
aumentar la expectativa de vida, mejorando así la calidad de vida de los pacientes que tienen algunas de
estas enfermedades genéticas. Las diferentes terapias que existen en la actualidad son muy diversas como
fármacos de uso en patologías comunes, terapia nutricional, fórmulas especiales, terapias de reemplazo
enzimático, trasplante de órganos y células hematopoyéticas, reducción de sustrato, oligonucleótidos
y la terapia génica. Al ser las enfermedades genéticas clínicamente heterogéneas, abre la posibilidad
de poder investigar cada vez más nuevas estrategias en un mayor número de enfermedades que en la
actualidad están olvidadas.
Palabras clave: Enfermedades genética; Terapia genética; Células Madre hematopoyéticas; Trasplantes;
Terapias (fuente: DeCS BIREME).
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INTRODUCTION
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A rare disease is defined by the appearance frequency.
That is why, for example, in Europe it is referred as the
one with an incidence of less than 1/2000 people.
The number of patients who are affected is estimated
between 6% to 8% of the general population. In our
country there are no studies that define the real
number of affected people, therefore it is estimated
that they are approximately 2 million of Peruvian
people(1). Nonetheless, some studies that were done
estimate that the percentage of affected people by a
rare disease may be between 3.5% to 5.9%.
The etiology of rare disease has a genetic origin in
80% of the total cases, and the other 20% has an
unknown origin. The genetic origin can be divided
into three groups: i) the ones that are produced by
variants in a unique nucleotide (SNV, nucleotide
variant), ii) variants of multiple nucleotides (MNV,
multinucleotide variant) and iii) variants in the
number of copies (CNV, copy number variation).
The first two variants mainly produce monogenic
diseases, which are estimated by the World Health
Organization (WHO) to number more than 10,000
entities(1). Pathogenic (or probably pathogenic)
CNVs that cause microdeletion/microduplication
syndromes; where the most frequent have a
prevalence between 1/1 000 to 1/25 000(3); although,
it has been reported that in fetuses the incidence
of CNVs is higher reaching 0.7%(4). It is important
to clarify that not all genetic diseases are rare. (e.g.
Down syndrome, Klinefelter syndrome)(5). Of this
large group of conditions, about 500 diseases have a
targeted treatment(6).
It should be noted that genetic diseases account
for up to 71% of pediatric hospitalizations(7) and
cause between 20% and 30% of deaths in this age
group(8). This proportion of patients generates a
large economic impact on health systems; thus, an
Australian study carried out in a population-based
cohort in 2010 found that patients with rare diseases
generated 10.5% of hospital expenses(9), in addition
to a longer hospital stay than their peers without
genetic conditions(7).
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The clinical manifestations of genetic diseases
are very diverse, i.e. they have a great clinical
or phenotypic variability and can manifest as
hypotonia, delayed psychomotor development,
intellectual disability, epilepsy, neuroregression,
congenital anomalies, short stature, microcephaly,
primary immunodeficiencies, schizophrenia, autism
spectrum disorders, conduct disorders, attention
deficit hyperactivity disorder, dementia, abnormal
movements and cancer. There are even entities,
such as infantile cerebral palsy, in which a genetic
component was not previously described and it
is now considered that up to 20% of cases have a
genetic cause(1). It is important to point out that
genetic diseases can appear at any stage of life, from
prenatal to adulthood(10).
Since the end of the 20th century, thanks to the
decoding of DNA and a better understanding of
the pathophysiology of genetic diseases, targeted
therapies, namely those that are directed at the
factor or factors that initiate the disease, have been
progressively and steadily increasing, which is aided
by bioinformatics(11).
Therapies for genetic diseases are available and their
use has been approved by international institutions
such as the Food and Drug Administration (FDA(12,13)
and the European Medicine Agency (EMA)(14,15). On
the other hand, there is a great expectation of new
treatments which are in basic research and some of
them in clinical research, as can be seen in the clinical
trials portal with more than 2,520 different studies(16).
In this review we aim to try to identify in a general
way the pharmacological treatment currently
existing and what is being investigated in these
genetic diseases. The way in which a therapeutic
approach is carried out is focused on one of the
points of the pathophysiological cascade of genetic
diseases. Thus, treatment could be at the level of
the affected gene(s) (e.g. gene and chromosome
therapy), replacing the abnormal protein (e.g.
hematopoietic cell transplantation), modifying
the metabolic cascade (e.g. special formulations,
substrate reduction therapy) and symptomatic(17)
(Figure 1).
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Figure 1. Therapeutic approach to genetic diseases. Some genetic conditions may involve one or more of
any of these links. For example, phenylketonuria can be managed by decreasing the amount of substrate
(phenylalanine) through special formulas or enzyme replacement therapy. Source: Sphingolipid lysosomal
storage disorders (17).

REVIEW ARTICLE

Fuente: Sphingolipid lysosomal storage disorders(17)

GENE THERAPY
The main objective of gene therapy (also known as
gene therapy) is to sufficiently incorporate a longlasting expression of a therapeutic gene or transgene
in order to improve or cure symptoms with minimal
adverse events(18).

1%
2%

When research began, it focused mainly on
monogenic diseases. However, currently most
clinical research studies are directed at cancer(19)
(Figure 2).

2%

12%
0%
6%
2%
2%
6%
67%

Source: Gene Therapy Clinical Trials Worldwide(19)

Figure 2. Proportion of diseases using gene therapy in clinical trials. Genetic diseases are the second most
frequently investigated group of conditions. Source: Gene Therapy Clinical Trials Worldwide (19).
Published by INICIB-URP, 2021
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The types of gene therapies are directed to germ
cells (sperm or egg cells) or somatic cells. The
duration of the expression of the transferred gene
depends on the type of pathology, for example, in
monogenic diseases the time should be prolonged,
while in multifactorial diseases (e.g. cancer, infectious
diseases) it should be short(20).

REVIEW ARTICLE

There are two types of gene transfer: in-vivo and exvivo(21). The former means that the gene is delivered
directly to a tissue, while in the latter, cells are
extracted from the patient, the gene is delivered
and then incorporated back into the affected

Abarca H et al

individual(18,21). The types of gene therapy can be
subdivided into those using virus-mediated therapy
and nanoparticles, synthetic short nucleotides, as
well as gene editing(22).

VIRUS-BASED THERAPIES
The most frequently used viruses are: adenovirus,
adeno-associated viruses, lentivirus, retrovirus(23,24)
(Figure 3). Adeno-associated viruses are the most
commonly used because they have a greater
capacity to infect different tissues and have a lower
inflammatory response(20).

A

B

C

Figure 3. A. Adenoviruses. They are constituted by a double stranded (double stranded) DNA, after
"infecting" the host cell, the genetic material is not incorporated into the genetic material of the host
(Episome). B. Adenoassociated viruses. Constituted by a single-stranded DNA, and after infection of the
host cell, the genetic material is not incorporated into the host genome. C. Lentivirus. They are a subtype of
retroviruses (RNA) derived from human immunodeficiency viruses, after the incorporation of RNA into the
host cell, this RNA uses a complex reverse transcription machinery to produce double-stranded DNA. This
double-stranded DNA is then incorporated into the host genome.
https://inicib.urp.edu.pe/rfmh/vol21/iss2/21
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Since 2016 to date, virus-based genotherapies have
been approved (by FDA and EMA), which we mention
below(18,25):
a. Alipogene
tiparvovec
-Glyberais
an
adeno-associated virus (AAV1) used for
hyperlipoproteinemia type 1 (MIM #238600)
caused by recessive variants of the LPL gene,
leading to lipoprotein lipase deficiency, causing
hyperchylomicronemia and pancreatitis(26).
b. Strimvelis, uses a retrovirus as a vector, which
is used in adenosine deaminase deficiency
(ADA gene), characterized by severe combined
immunodeficiency (MIM #102700)(27).

d. Voretigene neparvovec-rzyl -Luxturna- (AAV2),
approved for the use of recessive variants of the
RPE65 gene that causes Leber congenital amaurosis
(MIM #204100) and retinitis pigmentosa 20 (MIM
#613794)(29).
e. Onasemnogene abeparvovec-xioi -Zolgensma-

THERAPIES WITH SHORT
NUCLEOTIDES
Among the therapies that use short synthetic
nucleotides, there are two types:
a. Antisense oligonucleotides (AON, from antisense
oligonucleotide), have 20-30 nucleotides of DNA,
with two forms of action: i) using RNA Hase, in which
it destroys messenger RNA (mRNA) and ii) without
using RNA Hase, where it can act by modulating
splicing, through steric blocking, binding to the 5'
cap region of mRNA or the 3' poly A region(22,31-33)
(Figure 4A).
b. ARN de interferencia (ARNi), se utilizan como
mecanismo de defensa natural contra los virus ARN.
El mecanismo de acción es mediante la utilización
de los complejos moleculares Dicer (ribonucleasa)
y RISC (del inglés, RNA-induced silencing complex),
uniéndose de manera complementaria al ARNm y
su posterior rompimiento(22,31-33) (Figure 4B).

REVIEW ARTICLE

c. Zynteglo, using a lentivirus as a vector, is used in
beta-thalassemia (MIM #613985), characterized
by congenital hypochromic microcytic anemia,
decreased hemoglobin (Hb) A and increased Hb F,
hepatosplenomegaly(28).

(AAV9), which is used for spinal muscular atrophy
1 (MIM #253300), who are children presenting
progressive congenital hypotonia, where the
majority of those affected (95-98%) present a
deletion in exon 7 of the SMN1 gene(30).

A
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Figure 4. Mechanisms of action of short nucleotides A. Used by OAS to alter messenger RNA (mRNA). B.
Employed by RNA interference (RNAi).
To date, we have the following molecules approved
by the FDA and/or EMA:
a. Eteplirsen: is an AON used in patients with
Duchenne muscular dystrophy (MIM #310200)
and who present the deletion of exon 51 of
the DMD gene; causing a skipping of this exon
resulting in a short protein, however, with greater
functionality(34,35).
b. Nusinersen: is an AON used in spinal muscular
atrophy type 1 (MIM #253300), which is caused by
homozygous variants of the SMN1 gene. This AON
is used in patients who have at least one copy of
the SMN2 gene, modifying the expression of the
SMN2 gene (which is usually decreased), being a
protein similar to SMN1(36-38).
c. Paitisiran: is an RNAi used in transthyretin-related
hereditary amyloidosis (MIM #105210), caused by
heterozygous monoallelic variants in the TTR gene.
This RNAi causes the reduction of the "mutant"
protein(39).
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d. Mipomersen: is an AON used in familial
hypercholesterolemia (variants in the LDLR, APOB,
PCSK9 genes)(40).

GENETIC/GENE EDITION
On the other hand, it is of utmost importance to
know that greater possibilities are opening up with
the use of gene editing through meganucleases,
nucleases such as ZNF (zinger nuclear finger), TALE
(transcription activator-like repeat) and CRISPR/Cas9
(clustered regularly interspaced short palindromic
repeat / CRISPR associated protein 9). The latter
system is based on a system found in bacteria and
archae, which confers resistance to viruses. CRISPR/
Cas 9 contains two elements, an endonuclease (Cas
9) and a simple guide sequence (sgRNA) (Figure
5A). Uses range from gene regulation (Figure 5B5E), epigenetic modification to genome imaging.
Monogenic diseases under basic research include
congenital cataract, Duchenne muscular dystrophy,
hereditary tyrosinemia type 1, cystic fibrosis,
betatalasemia, urea cycle disorders(41).
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B

GENE THERAPY USING NON-VIRAL
VECTORS
These are research strategies that have the possibility
of incorporating DNA through synthetic vectors,
which are frequently known as nanoparticles (NPs)
measuring 10 to 500 nm(23). These NPs have the
advantage of very easy synthesis, lower production
costs than viral vectors, greater safety, the
capacity to transport larger molecules and greater
efficacy(23). These nanoparticles can be composed of
polysaccharides, solid lipids or coated with CK30PEG
(30-mer cationic polylysine conjugated with 10KDa
polyethilene glycol)(23). On the other hand, the
incorporation of DNA is being tested with the use
of a vector ("naked" DNA) by means of physical
methods such as electroporation, sonoporation,
magnetofection and "bullet" genes(20).

NUTRITIONAL THERAPY
This type of therapy is mainly used for inborn errors
of metabolism (IEM)(42). It is important to emphasize
that there are at least 81 pathologies that, with early
diagnosis and timely treatment, will prevent the risk
of intellectual disability (www.treatable-id.org)(43). It
is of utmost importance to emphasize that the ideal
moment of diagnosis is as early as possible, and if

Published by INICIB-URP, 2021
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Figure 5. CRISPR/Cas9 A. CRISPR/Cas9 system. PAM= protospacer adjacent motif, N=A, R=G or A. = Cas9
protein. Sg=single guide. Mechanisms of action of the CRISPR/Cas9 system. B. Cas9 and sgRNA cause gene
disruption (knock out). C. Cas9, two sgRNAs plus one DNA strand insert a gene (knock in). D. Cas9 and two
sgRNAs deletes a gene. E. Cas9, sgRNA and a DNA template correct a genetic variant ("mutation").
possible through universal neonatal screening of at
least the most frequent entities(44). We can divide this
type of therapy into(45,46) (Table 1):
a. Nutrient restriction
When it is known that there is an increase in a toxic
metabolite due to a decrease in enzymatic activity,
and that there are other metabolites cascading
above; what is done is to reduce these through
special formulas, causing the toxic to decrease,
thus avoiding the onset of the pathophysiological
cascade(47,48).
b. Nutritional supplementation
In many cases, apart from nutrient restriction with
special formulas, it is necessary to supplement
with metabolites that are not adequately
produced(45,46).
c. Elimination or blocking of toxic metabolite
synthesis
There are many IEM, where the pathophysiology
of the picture is mainly framed in the alternative
production of a toxic metabolism, so it is
necessary to use drugs or procedures (e.g. the
use of hemofiltration in urea cycle defects) that
eliminate or block the synthesis of these(45,46).
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276600

248600

Fumarylacetoacetate

Tyrosine transaminase

Dihydrolipoamide
branched-chain
transacylase, BCKA betasubunit decarboxylase,
BCKA alpha-subunit
decarboxylase.

Isovaleryl CoA
dehydrogenase

Succinylacetone, tyrosine, FA,
methionine. Severe liver disease, renal
tubular disorder, rickets.

Tyrosine , normal FA. Herpetiform corneal
ulcers and punctate keratosis of fingers,
palms and soles, DI.

↑Leucine, ↑isoleucine, ↑valine.
Matchstick maple syrup od or, neonatal
encephalopathy.

Isovalerylacidemia, metabolic acidosis,
RDPM, epilepsy, cerebral hemorrhage,
neutropenia, leukopenia, pancytopenia.

Tyrosinemia Ia, Ib
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Tyrosinemia II

Maple syrup-colored urine
disease

Isovaleric acidemia

Leucine

Leucine

phenylalanine and 
tyrosine

phenylalanine and 
tyrosine

phenylalanine and 
tyrosine

phenylalanine and 
tyrosine

Aminoácidos

Special formulation

L-carnitine: 100 mg/kg/day.
Glycine 200-400 mg/kg

Oral thiamine: 100-300 mg/
day. L-Valine, L-isoleucine

3-omega fatty acid
supplementation

NTBC 1-2 mg/kg/day

Tetrahydropterin: 2mg/kg

L-tyrosine, long
neutral amino acids,
tetrahydropterin

Supplementation,
dietary,
considerations and
other treatments

51

50

50

49

48

47, 48

References
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243500

276700

261630

Dihydropteridine quinoid
reductase

Phenylalanine.Do not respond adequately
to special formulations with FA , RDPM,
DI, axial hypotonia and appendicular
hypertonia, epilepsy.

Hyperphenylalaninemia,
BH4 deficiency

261600

Phenylalanine
hydroxylase

Mim o ps

Phenylalanine, profound and irreversible
intellectual disability.

Enzyme deficiency

Phenylketonuria

Disease

Clinical features without timely
treatment

Table 1. Management of some inborn errors of amino acid, carbohydrate and lipid metabolism.
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606054 y
251000

Glutaryl CoA
dehydrogenase

Homocysteine, ectopia lentis, RDPM, DI

Glutaric acid, glutaconic acid. Acute
encephalopathy, macrocephaly, basal
ganglia lesions.

Lysine. Recurrent vomiting, diarrhea, coma
SLC7A7 (solute carrier
episodes, aversion to protein-rich foods,
familiy 7, member 7)
hepatomegaly and muscular hypotonia.

Acute deterioration, metabolic acidosis,
ammonium. Early death or neurologic
disorder, chronic renal disease,
cardiomyopathy.

Homocystinuria

Glutaric acidemia type 1

Lysinuric protein
intolerance

Propionic and
methylmalonic acidemia

Methylmalonyl CoAmutase and propionyl
CoA carboxylase

222700

Cystathionine β-synthase

3-methylglutaconic aciduria. In type
1, lack of medro, optic atrophy, spastic
quadriplegia, dystonia, hyperreflexia,
3-methylglutaconic aciduria are observed.

3-Methylglutaconic
aciduria

231670

236200

methionine and 
cysteine

methionine, isoleucine,
threonine, valine

protein intake

Biotin: 5-10 mg/day. B12
10-20 mg/day. L-Carnitine:
100 mg/kg/day.

L-citrulline: 2.5-8.5 g/day in
4 doses.

57

56

55

54

Folic acid: 500-1000/ mg/ 3
times per day. Betaine: 150
mg/day. Pyridoxine 25-750
mg/day. B12 1 mg (IM), 1020 mg (oral).

Leucine

Riboflavin: 100-300 mg/
day.

53

L-carnitine: 100 mg/kg/
day. Glycine 250-400 mg/
kg/day. Pantontenic acid:
15-150 mg/day.

lysine and  tryptophan

52

L-carnitine: 100 mg/kg/day.

valine

REVIEW ARTICLE
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PS250950

9 different enzymes

Organic acidemia, lactate, 3-OH-isobutyric
aciduria.

3-OH-isobutyric aciduria

236795

Defects of the respiratory
chain or defects of
methylmalonate
semialdehyde
dehydrogenase.
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Galactose 1-phosphate
uridylyltransferase

Glucose 6-phosphatase
or glucose 6-phosphate
transporter

Fructose 1-phosphate
aldolase

Cationic organic
transporter 2, carnitine
palmitoyltransferase
type 1A and 2, carnitineacylcarnitine translocase,
VLCAD, mitochondrial
trifunctional protein

Galactose 1-phosphate↑. Swallowing
problems, failure to thrive, hepatocellular
damage, bleeding, E. coli sepsis, RDPM,
language disorder, premature ovarian
failure, cataract.

Hepatomegaly, nephromegaly,
hypoglycemia, lactic acidosis, uric acid↑,
lipids↑, triglycerides↑, seizures. "Doll"
facies, short stature, chronic neutropenia,
xanthoma, diarrhea.

Glucose, lactic acidemia, phosphorus ↓, uric
acid ↑,, magnesium ↑, alanine↑. Nausea,
vomiting, lack of medro, acute lethargy,
convulsions, coma. Hepatic and renal
failure.

Hypoglycemia, ketones↓↓↓, insulin ↑ free
fatty acids↓. Cardiomyopathy, myopathy.

Urea cycle disorders

Classic galactosemia

Glycogenosis type I
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Hereditary fructose
intolerance

Long-chain fatty acid
oxidation defects

Heterogeneous

229600

232200

230400

Heterogeneous

Lipid s:  15-20 %  of  total
calories

Lipids

Fructose <10  mg/kg

Eliminate lactose, fructose,
sorbitol

L-carnitine: 100 mg/kg.
Dietary fractionation. MCT:
30% of total lipids, DHA

Vitamin C

Compound carbohydrates:
raw starch (1.5-2 g/kg/
dose). Dietary fractionation

Eliminate galactose (lactose,
Soy milk. Elemental calcium
galactolipids)

Carbohydrates

amino

L-arginine: 200-400 mg/
kg. L-citrulline: 200-400
mg/kg/day. Sodium
benzoate: 250-500 mg/kg/
day, hemofiltration and
hemodialysis with ECMO,
carbamyl glutamate.

62

61

60

59

58
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FA= phenylalanine, RDPM= psychomotor developmental delay, DI= intellectual disability, NTBC=, ECMO=extracorporeal membrane oxygenation. VLCAD= very long chain acyl-CoA dehydrogenase.

Carbamoyl phosphate
synthetase I, ornithine
transcarbamylase,
argininosuccinic
acid synthetase,
argininosuccinic acid
lyase, arginase, N-acetyl
glutamate synthetase,
ornithine translocase,
citrinase.

Ammonium↑↑↑, in cases with severe
enzyme deficiency, lethargy, anorexia,
hyper- or hypoventilation, consvulsions
and coma are observed. In cases with mild
deficiency, ammonium is elevated due to
a trigger (acute illness or stress), with loss
of appetite, vomiting, lethargy, delusions,
hallucinations, psychosis and acute
encephalopathy.
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HEMATOPOIETIC CELL
TRANSPLANTATION
Known as hematopoietic stem cell transplantation
(HSCT), which is widely used in different genetic
diseases. This type of therapy is available and proven
effective for primary congenital immunodeficiencies
(e.g. Duncan disease), osteogenesis imperfecta
and lysosomal storage diseases (LSD) (Figure
6), such as X-linked adrenoleukodystrophy,
mucopolysaccharidosis I, II, VI and VII; metachromatic
leukodystrophy, fucosidosis and mannosidosis(64-67).

It is of utmost importance that the effectiveness of
therapy will depend to a greater or lesser degree as
long as the patient is asymptomatic or minimally
affected(65,66).

REVIEW ARTICLE

The rationale for applying HSCT in lysosomal storage
diseases (LSD) is based on the ability of transplanted
cells and/or their cell progeny (or clones) to
contribute to the macrophage populations of
affected tissues and thus become permanent local
sources of functional lysosomal enzymes; in this
way metabolically active cells can improve the
disease phenotype by removing storage material
and modulating local inflammation at diseased sites.
Cell turnover with the donor after transplantation is

supposed to affect all types of tissue-bound myeloid
populations, including myeloid cells and possibly
microglia in the brain. For this reason, HSCT was
intended as an avenue for treating enzyme-deficient
patients with severe central nervous system (CNS)
involvement. Importantly, if complete donor
chimerism is achieved, HSCT is a unique intervention
capable of providing a lifelong source of enzymes for
the affected patient. The donor cells also re-establish
a new immune system in the patient, overcoming
pre-existing ones and preventing post-treatment
immune responses directed at the functional
enzyme. On this basis, since the first LSD patients
were transplanted in the early 1980s, a few thousand
LSD patients have been treated with allogeneic HSCT
over the past decades(68). (Figure 6).

Figure 6. Mechanism of action of hematopoietic cell transplantation. The donor cell will synthesize the
deficient enzyme (E), which will be captured by the deficient cells, through the 6-phosphate mannose
receptor (M6), integrating this complex into the lysosome to subsequently degrade the metabolic complexes.

ENZYME REPLACEMENT THERAPY
(ERT)
There are many pathologies of genetic origin that

Published by INICIB-URP, 2021

by delivering the defective protein will change the
natural history of the disease. Within this group of
entities are lysosomal depot diseases and adenosine
deaminase deficiency(69-78) (Table 2).
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607014, 607015,
607016

309900

253000

253200

232300

230800

Mucopolysaccharidosis I

Mucopolysaccharidosis II

Mucopolysaccharidosis
IV A

Mucopolysaccharidosis VI

Pompe Disease

Gaucher Disease

81

Galsulfase

Alglucosidase alfa

Imiglucerase
Velaglucerase
Taliglucerase

Coarse facies, macrocephaly, skeletal dysplasia,
hepatosplenomegaly, pulmonary and cardiac involvement,
progressive joint contractures, claw hand.

Progressive loss of muscle strength, at birth can be observed
as hypotonia and cardiomegaly.

Thrombocytopenia, splenomegaly, bone involvement.

70

Elosulfase alfa

Coarse facies, skeletal dysplasia predominantly thoracic,
pulmonary and cardiac involvement, corneal opacity,
hyperlaxity in hands.

74,75

74,75

74,75
78

Idursulfase
Hunterase

Coarse facies, macrocephaly, skeletal dysplasia,
hepatosplenomegaly, variable neurological involvement,
pulmonary and cardiac involvement, progressive joint
contractures, claw hand.

74,75

References

Laronidase

Approved TRE
(FDA and/or EMA)

Coarse facies, macrocephaly, skeletal dysplasia,
hepatosplenomegaly, variable neurological involvement,
pulmonary and cardiac involvement, progressive joint
contractures, corneal opacity.

Main clinical characteristics
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GBA

GAA

ARSA

GALNS

IDS

Affected gene

MIM

ntity

Table 2. Enzyme replacement therapy in genetic diseases.
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278000

102700

261600

204500

Adenosine deaminase
deficiency

Phenylketonuria

Neuronal ceroid
lipofuscinosis type 2

241500, 241510

Lysosomal acid lipase
deficiency

Hypophosphatasia

301500

TPP1

PAH

ADA

LIPA

ALPL

AGA

Cerliponase alpha

PEG-ADA

Severe combined immunodeficiency due to accumulation
of toxic metabolites causing malfunction and formation of
lymphocytes.

Onset at 2-4 years of age with epilepsy, neuroregression,
myoclonic ataxia, pyramidal signs, visual impairment (4-6
years of age).

Sebelipase alfa

Malnutrition, hepatomegaly with hepatic failure, calcification
of the adrenal glands. Cholesterol ester deposition disease.
Cirrhosis, hypersplenism, intestinal malabsorption.

Pegvalase

Asfotase alpha

Decreased bone and dental mineralization. Variable
presentation from pathological fractures, chondrocalcinosis,
"myopathy", early loss of deciduous teeth, short stature.

Used in adult patients with phenylketonuria.

Agalsidasealpha
Agalsidase beta

Acroparesthesias, angiokeratomas, chronic renal disease,
cardiac involvement, cornea verticilata,
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Fabry Disease

77

70

76

73

69,79
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CHAPERONAS
Migalastat is currently approved for use in Fabry
disease (MIM #301500). Chaperones have the
function of stabilizing the usual activity of a
protein(79).

REVIEW ARTICLE

TERAPIA DE REDUCCIÓN DEL
SUSTRATO
Substrate reduction therapy consists of reducing
the metabolite(s) one step upstream of the
affected pathway. Miglustat and eliglustat are
held as therapeutic weapons for diseases such
as Gaucher 1 (MIM # 230800) and Niemann-Pick
type C (MIM #257220)(80–82). There are many reviews
that genistein has this mechanism of action in
mucopolysaccharidoses (e.g. type III)(83).

CHROMOSOME THERAPY
Se encuentra en investigación básica y se basa en
mejorar el efecto de las duplicaciones o deleciones
parciales o totales. Dentro de las estrategias utilizadas
se tiene(84,85):
Silenciamiento de cromosomas con XIST, el cual
consiste en utilizar nucleasas (ej. ZNF) para insertar
una forma inducible del gen XIST en una de las
copias en las células trisómicas (Figure 7A).
a. Positive-negative selectable markers on the extra
chromosome; the thymidine kinase-neomycin
(TKNEO) transgene is used, which helps to select
with antibiotics and then isolate disomic cells from
a trisomic population. The fully trisomic cells (iPSCsinducible pluripotent stem cells) are infected with
an adeno-associated viral vector (AAV) containing
a TKNEO transgene that confers neomycin (NEO)
resistance and sensitivity to ganciclovir. Due
to imperfect efficiency, only some cells in the
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population receive the TKNEO transgene. The cell
population is treated with neomycin, after which
the cells that do not contain the TKNEO transgene
are removed. The population containing the pure
transgene is proliferated to allow nondisjunction
events to occur naturally. The cohort of disomic and
trisomic cells is then treated with ganciclovir (GCV);
all trisomic and TKNEO transgene-containing
cells are removed leaving only the pure disomic
population that can be isolated and proliferated
(Figure 7B).
b. Drug-induced trisomic rescue; where trisomic cells
(trisomy 21 and 18) are cultured with ZSCAN4,
which increases the number of euploid (normal)
cells by 24%.
c. Artificial
human
chromosomes
(HAChuman artificial chromosomes); known as
minichromosomes, which are used as "vectors".
These are freely integrated into the cell cycle over
time, which would have the possibility of correcting
deletions.
d. Induction of ring chromosome formation. In
trisomic cells (iPSCs) LoxP is inserted into the short
and long arm of the chromosome through CRISPRCas9. Then the cells are treated with a recombinase
that induces the formation of ring chromosomes,
then these cells replicate and lose the ring
chromosome naturally, restoring the disomic state.
e. Inhibition of the DYRK1A gene, it has been
demonstrated that this gene is involved in the
physiopathology of the intellectual disability
of Down syndrome. One of the drugs that has
demonstrated its efficacy and safety in adult
patients (phase 2) with Down syndrome is
epigallocatechin-3-gallate (green tea extract),
improving cognition, visual recognition memory,
inhibitory control and adaptive behavior(86,87).
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Figure 7. A. Silencing of aneuploid chromosomes by inserting XIST. In trisomic cells (iPSCS) the XIST
(red) is incorporated into one of the chromosomes by ZNF, then the cells are treated in order to activate
(transcribe) the XIST, thus silencing the entire extra chromosome (red), which is subsequently observed as a
Barr corpuscle, re-establishing a "disomic" state. B. Use of selectable positive-negative markers on the extra
chromosome.
OTHER THERAPIES
Some monogenic diseases currently have therapies
under clinical investigation, which could be verified
at www.clinicaltrials.com.
Some of the therapies shown are probably not
directly focused on what is described in Figure 1;
however, they have been shown to have enormous
utility in the management of these diseases.
Duchenne muscular dystrophy (DMD) is a pathology
manifested by progressive loss of muscle strength
in the first decade. Three therapies are currently
available, one of them we mentioned in short
nucleotide therapies, and the others are the use
of deflazacort and ataluren. Deflazacort has been
widely used in DMD for more than 30 years; however,
it was only approved by the FDA in 2017(88).
Ataluren is used in those patients who have a
nonsense variant (10-15% of DMD patients). Its
mechanism of action is to perform a reading jump at
the site of the nonsense variant, making the protein
larger than the "mutated" protein. In this way it
causes the phenotype to change to Becker muscular
dystrophy(89).

Published by INICIB-URP, 2021

In this same sense, the use of bisphosphonates
in diseases such as osteogenesis imperfecta
(PS166200) and McCune-Albright syndrome (MIM
#174800) are indicated to reduce pain and the risk of
the appearance of fractures(90,91).
Other therapies in osteogenesis imperfecta
that have been observed to decrease the risk of
fractures is through the activation of osteoclasts
(denosumab), bone anabolic agents (teriparatide,
romosozumab)(67).
X-linked hypophosphatemic rickets (MIM #307800)
is a condition in which chronic hypophosphatemia
is observed which causes a failure in mineralization
leading to rickets and osteomalacia. A monoclonal
FGF23 inhibitor (burosumab) has been shown to be
a promising therapy in this condition(92).
Tuberous sclerosis (MIM #PS191100) has very
heterogeneous clinical manifestations and the
FDA has approved the use of mTOR inhibitors such
as everolimus for epilepsy, rhabdomyosarcomas,
astrocytomas, angiomyolipomas; and rapamycin for
lymphangioleiomyomatosis(93).
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CONCLUSION
The pharmacopoeia in genetic diseases is increasing
notably over time. Many therapies try to be very
specific; however, drugs are being developed that
will be used in more than one entity, which are even
etiologically unrelated.

REVIEW ARTICLE

As we are seeing in recent years, these new therapies
are changing the natural history of this group of
entities. However, the bottleneck in these conditions
is diagnosis, either due to the limited number of
specialists, lack of implementation, high costs,
insurance coverage, among others.
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The future of medicine in general is conditioned
to better understand the underlying and inherent
mechanisms of each disease, based on an individual
understanding of our "omics", thus taking it to
another level of medicine: Precision Medicine.
Finally, it is important to indicate that all these
therapies and drugs are promising and valuable
therapeutic options for these different diseases
described; however, it is of utmost importance that
the management of all these conditions is multi
and interdisciplinary and carried out by qualified
professionals within laboratories and institutions
properly certified for these purposes.
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